Mission Therapeutics has been awarded $5.2m from The Michael J Fox Foundation and Parkinson’s UK to advance its potential disease-modifying treatment MTX325. MTX325 is a potent, selective, small molecule brain-penetrant USP30 inhibitor, which is designed to protect dopamine-producing neurons by improving mitochondrial quality and function. The funding will support a 28-day dosing of MTX325 in patients with early-stage Parkinson’s disease (PD), as part of Mission’s ongoing MTX325 Phase I programme. Dosing for patients with early-stage Parkinson’s disease is expected to start early in 2025. Dr P…